Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Tag Archives: oral

Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics

By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently…

Off-Label Antidepressant Use in Pediatric Patients with...
November 1, 2014 - Clinical , Featured

By: Jacqueline Meaney, PharmD Candidate c/o 2015, University at Buffalo: School of Pharmacy and Pharmaceutical Sciences — Psychotropic medications are typically used in conjunction with cognitive behavioral therapy to treat behavioral problems that affect children with autism spectrum disorder (ASD). Symptoms of ASD typically include a need for routines (change intolerance), difficulty with verbal and…

Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics

By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk…

Anticoagulation in Pregnant Women: Which Medications ar...
October 1, 2014 - Clinical , Featured

By: Diana Gritsenko, PharmD Candidate 2015 – Multiple complications can arise during pregnancy. While venous thromboembolism (VTE) has a prevalence rate of just 0.06% it is one of the leading causes of maternal mortality. It is recommended that at-risk pregnant women receive anticoagulation therapy for a minimum of 3 months and VTE prophylaxis for the…

FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics

By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the…

Grastek®: FDA Approves New Sublingual Immunotherapy fo...
July 1, 2014 - Featured , In the News / Politics

By: Kevin Lin, PharmD Candidate c/o 2015 – This April, the FDA approved three sublingual immunotherapies for pollen induced allergic rhinitis: Grastek® (Timothy Grass Pollen Allergen Extract), Oralair® (Grass Pollen Allergen Extract), and Ragwitek® (Short Ragweed Pollen Allergen Extract). Formulated by Merck, Grastek® is Timothy grass pollen allergen extract. It is approved for patients ages…

The Dangers of Intrathecal Baclofen...
June 1, 2014 - Clinical , Featured

By: Ada Seldin, Staff Editor – Intrathecal baclofen (ITB) is indicated for the treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, spinal ischemia or tumor, transverse myelitis, cervical spondylosis, cerebral palsy, and degenerative myelopathy.1 Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal cord level by decreasing excitatory neurotransmitter release from…

I Have a Problem...
June 1, 2014 - Featured , Professional Advice / Opinions

By: Sang Hyub Kim, DPM Candidate c/o 2018, New York College of Podiatric Medicine – I was diagnosed with ulcerative colitis in 2009. For the past five years, I have literally taken tons of immunosuppressant medications, ranging from corticosteroids (prednisone), to chemotherapeutics (6-Mercaptopurine) in an effort to suppress the inflammation in my colon. Currently, I…

The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured

By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There…

New Strides in Lupus Treatment...
April 1, 2014 - Featured , In the News / Politics

By: Daniel Mathan, PharmD Candidate c/o 2016, Anita Kachappilly, PharmD Candidate c/o 2016, & Amrita Singh, PharmD Candidate c/o 2015 – Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease that affects multiple organs in the body and can potentially become life threatening.1 The incidence of SLE is about 50 cases for every 100,000 people; it…

Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured

By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.…

Tasimelteon (Hetlioz®): First FDA Approved Pharmacolo...
April 1, 2014 - Featured , In the News / Politics

By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and…

The Increasing Roles of Pharmacists in Transplant Outco...
February 1, 2014 - Featured , In the News / Politics

By: Jenny Park, PharmD Candidate c/o 2015 – Medication adherence is a big part of a patient’s success in managing their health conditions. The Annals of Internal Medicine estimated that the cost of medication non-adherence may reach up to $289 billion each year.1 It is crucial for organ transplant patients to take powerful immunosuppressants to…

The Use of Methadone in Neuropathic Pain...
January 1, 2014 - Clinical

By: Neal Shah, PharmD, MD/PhD Student c/o 2021, West Virginia University School of Medicine – Methadone is a powerful long-acting mu-opioid agonist that has been traditionally used in the management of chronic pain, treatment of pain refractory to certain opioid agents, and maintenance of opioid addiction.1-5 While neuropathic pain is not traditionally linked to mu-opioid…

The Blunt Truth...
January 1, 2014 - Featured , In the News / Politics

By: Katharine Cimmino, Editor-in-Chief – Marijuana, also known as “grass,” “pot,” “joint,” “weed,” “reefer,” “hashish,” and “Mary Jane,” is a very popular illicit drug.1 According to the National Survey on Drug Use and Health, “In 2012, 5.4 million persons aged 12 or older used marijuana on a daily or almost daily basis in the past 12…

Phi Lambda Sigma’s 12th Annual Healthy Halloween...
December 1, 2013 - Events

By: Taryn Mondiello, PharmD Candidate c/o 2015 – Halloween came early this year to St. John’s University and to the children at the “Hour Children” program in Long Island City. On Wednesday October 30th, Phi Lambda Sigma, also known as the Pharmacy Leadership Society, hosted their 12th Annual Healthy Halloween, a Halloween celebration for local…

Possible Inhaled Option for Diabetics...
December 1, 2013 - In the News / Politics

By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose…

Still a Long Road Ahead for New Hepatitis C Treatment...
December 1, 2013 - In the News / Politics

By: Ramya Mathew, PharmD Candidate c/o 2015 – Vertex Pharmaceuticals, an American biotechnology company based in Cambridge, Massachusetts, has been researching a new “nuke” for the treatment of Hepatitis C called VX-135. This nucleotide polymerase inhibitor is currently undergoing clinical trials, but the FDA has put the research on a partial hold due to findings…

Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical

By: Arya Mathew, PharmD Candidate c/o 2014 –  About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men.  Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head.  Along with the severe pain, migraine sufferers also experience…

Nature’s Remedy… in a More Palatable Dosage Form...
November 1, 2013 - Featured , In the News / Politics

By: Davidta Brown, Staff Editor – Pathogenic bacteria have been enemies to human health for centuries. As recently as last month, the Centers for Disease Control published an 80-page document informing the public about America’s biggest microbial threats. Most of the pathogens on the list exhibit antibacterial resistance. One particular bacterial species, ranked at threat…

New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical

By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who…

New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured

By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to…

Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics

By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms…

Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical

By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily…

HIV Test: Making a Difference...
September 1, 2013 - In the News / Politics

By: Sang Hyo Kim, Staff Editor – On June 27, 2013, the Centers for Disease Control and Prevention (CDC), AIDS.gov, and other national and local entities organized the 19th annual National HIV Testing Day. On this day, the theme of “Take the Test, Take Control” was employed to spread awareness of testing and prevention methods…

Novel Virus, Standard Vigilance...
September 1, 2013 - Featured , In the News / Politics

By: Davidta Brown, Staff Editor – When the seasons transition from winter into spring every year, healthcare providers brace for a shift into a time of increased sneezes, requests for cough medication, and vaccinations, otherwise known as flu season. The rounds of illness that pass each year are usually more of an annoyance than a…

Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured

By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and…

Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured

By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated…

Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured

By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has…

Compounding at a Crossroads: New Boundaries in the Afte...
July 1, 2013 - Featured , In the News / Politics

Davidta Brown, PharmD Candidate c/o 2017 –      The debate on the nature of compounding practice and the extent to which it ought to be regulated has come to the forefront of public attention.  Those who regularly follow American news and politics are familiar with the series of events that have led to the present…

FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured

By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen…

FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured

By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction…

Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical

By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the…

New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical

By Nancy Rizkalla, PharmD candidate c/o 2015 –        Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –…

FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured

By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications.  This…

New Healthcare Law Concerning Birth Control Causes Deba...
January 1, 2013 - Featured , In the News / Politics

By: Katie Cimmino, Pharm D. Candidate c/o 2015 –  With the start of the New Year the French government is enacting a new law concerning contraceptives. Now girls between the ages of 15 to 18 will be able to obtain free birth control.  Not only will they have access to it, but the French government…

FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…

Adverse Events from Ingestion of OTC Eye Drops and Nasa...
December 1, 2012 - Featured , In the News / Politics

By Tasnima Nabi, PharmD Candidate c/o 2016 – The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been…

Safety and Efficacy of Atropine for Salivary Hypersecre...
November 1, 2012 - Clinical

By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2  Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2  It also has functions in the central nervous system (CNS); it could stimulate or…

New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical

By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1  It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1  These patients tend to…

Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured

By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1  The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for…

Medications Causing Body Temperature Fluctuations...
October 1, 2012 - Clinical , Featured

By: Elsa Thomas, Pharm.D. c/o 2013 – Human body uses various complex mechanisms to maintain its body temperature within a narrow range despite extreme environmental temperature changes as well as physiological changes. Several factors can affect body temperature such as disease states, growth, exercise, hormonal changes, and medications. Hypothermia can occurs as a result of…

Brand Vs. Generic: What Every Prescriber Should Know...
September 1, 2012 - Clinical , Featured , Professional Advice / Opinions

By: Marina Yermolayeva, PharmD Candidate c/o 2013 – “I’m allergic to the generic; I need the brand name medication,” is a common claim heard by many health care providers.  Managed care organizations get numerous calls from doctors and patients requesting prior authorizations to approve brand name medications whilst there are generic alternatives available on formulary.…

Quick Update: Triptan Pharmacology...
August 1, 2012 - Clinical

By: Neal Shah, Co-Editor-In-Chief – Migraines can be “classic” or “common.”  While all migraines feature unilateral, pulsating headaches, classic migraines feature an “aura” upon onset (whereas common migraines do not).  Pharmacologic treatment of migraines generally includes serotonin agonists (triptans).1 Triptans are selective agonists of the 5-hydroxytryptamine 1B and 1D (5HT1B/1D) subtypes.  By activating these receptors,…

The Role of N-Acetylcysteine in Contrast Induced Nephro...
August 1, 2012 - Clinical

By: Neal Shah, Co-Editor-In-Chief – Contrast dyes enhance imaging for computer tomography (CT), magnetic resonance (MR), and X-rays.1  Dyes usually consist of barium, iodine, or gadolinium, depending on the procedure.2  CT and X-ray scans often use iodine for systemic imaging and barium sulfate for GI imaging, whereas MR imaging primarily uses gadolinium.2  Gadolinium and iodine…

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

Artificial Saliva Agents in Xerostomia...
July 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants, analgesics, diuretics, and antihistamines have a high propensity to cause xerostomia.1  Xerostomia may also result from Sjogren’s syndrome, Parkinson’s disease, and various chemotherapy agents.2  Traditionally, muscarinic agonists like pilocarpine have been used to reverse xerostomia.…

Matching Challenge: Look-Alike, Sound-Alikes...
June 1, 2012 - Puzzles

By: Addolorata Ciccone, Pharm.D. Candidate c/o 2013 – The following medications are easily confused.  Try to match each one with its corresponding fun fact.  This capsule should be swallowed whole; if chewed or dissolved orally, oropharyngeal anesthesia may occur, which poses a choking hazard.  Drinking a glass of water can help bypass this potential adverse…

Proton Pump Inhibitor Use and Complications...
June 1, 2012 - Clinical

By: Lauren Kaveski, Pharm.D. Candidate c/o 2013 – We see proton pump inhibitors (PPIs) used in many medication regimens, but it is unknown whether the majority of patients receive these medications for appropriate durations or indications.  For all labeled indications, other than Zollinger-Ellison Syndrome (a rare condition characterized by damaging gastrin hypersecretion and subsequent hydrochloric…

CHF, a Rare but Serious Presentation of Graves’ disea...
March 1, 2012 - Clinical , Featured

By: James Schurr, Pharm.D. Candidate c/o 2014 – Graves’ disease is an autoimmune disorder that results in a state of thyrotoxicosis, or a cause of hyperthyroidism, due to the Immunoglobulin G-mediated agonism of thyroid stimulating hormone (TSH) receptors located on the thyroid.  Stimulation of TSH receptors causes an increase in circulating thyroxine (T4) and triiodothyronine…

Post navigation

← Older posts


Do You Want to be a Published Author? Submit your Article(s) Today!



Tweets by @RhoChiPost

HOME: Home Page

VOLUMES / ISSUES: 14 . 13 . 12 . 11 . 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List


Copyright © 2011-2025 Rho Chi Post